Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Shares of Eli Lilly ( LLY -10.79%) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m. ET. The leg down comes as ...

Jared Holz, Mizuho Securities health care strategist, joins 'Fast Money' to discuss Eli Lilly's biggest day drop since 2008 ...

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Eli Lilly CEO Dave Ricks took a stand against Trump's tariffs in a Q1 earnings call. The medicine company has strong operations for obesity and weight loss drugs in Ireland.

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

Eli Lilly's weekly prescription data for Zepbound is up 354% year over year while Novo Nordisk's Wegovy is up just 61%.

NewEdge Wealth CEO Rob Sechan owns it and breaks it down, while the Investment Committee drops their latest picks.

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.